Balyasny Asset Management
GTHX

Balyasny Asset Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Balyasny Asset Management’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,614
Closed -$67.5K – 3236
2024
Q1 		$67.5K Buy
+15,614
New +$54.4K ﹤0.01% 2512
2023
Q1 		– Sell
-13,241
Closed -$71.9K – 3264
2022
Q4 		$71.9K Buy
+13,241
New +$111K ﹤0.01% 2295
2022
Q3 		– Sell
-28,394
Closed -$140K – 3352
2022
Q2 		$140K Sell
28,394
-781
-3% -$4.33K ﹤0.01% 2246
2022
Q1 		$222K Buy
+29,175
New +$277K ﹤0.01% 1996
2019
Q1 		– Sell
-15,135
Closed -$290K – 1715
2018
Q4 		$290K Buy
+15,135
New +$567K ﹤0.01% 1237
2018
Q3 		– Sell
-6,554
Closed -$285K – 2114
2018
Q2 		$285K Buy
+6,554
New +$281K ﹤0.01% 1538

Other funds holding GTHX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Balyasny Asset Management's GTHX Position: Q2 2024 in Review

Balyasny Asset Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2024, closing a stake of 15,614 shares — an estimated $67.5K sold.

Balyasny Asset Management first reported a position in GTHX in Q2 2018 and held it in 6 quarters. The position peaked at $290K in Q4 2018. 88 funds tracked by Wall St. Rank hold GTHX as of Q2 2024.

  • Balyasny Asset Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 15,614 G1 Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $67.5K.
  • Balyasny Asset Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2018 and held it in 6 quarters.
  • Balyasny Asset Management's G1 Therapeutics, Inc. Common Stock position peaked at $290K in Q4 2018.
  • 88 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.